合用CPY450酶抑制剂对伏立康唑安全性和药代动力学的影响的系统评价

doi:10.5246/jcps.2017.03.021

中国药学(英文版) ›› 2017, Vol. 26 ›› Issue (3): 202-211.DOI: 10.5246/jcps.2017.03.021

合用CPY450酶抑制剂对伏立康唑安全性和药代动力学的影响的系统评价

杨会霞^1,2, 陈恳^1,3, 梁舒瑶^1,3, 翟所迪¹, 易湛苗^1*

1. 北京大学第三医院药剂科, 北京 100191
2. 清华大学玉泉医院药剂科, 北京 100040
3. 北京大学医学部药学院药事管理与临床药学系, 北京 100191

收稿日期:2016-12-27 修回日期:2017-02-13 出版日期:2017-03-30 发布日期:2017-02-19
通讯作者: Tel.: +86-010-82265740, E-mail: yizhanmiao@163.com
基金资助:
The Medical Education Research Project from Society of Medical Education and Medical Education Committee of China Association of Higher Education (Grant No. 2016B-YX007).

Effect of cytochrome P-450 inhibitors on pharmacokinetics and safety of voriconazole

Huixia Yang^1,2, Ken Chen^1,3, Shuyao Liang^1,3, Suodi Zhai¹, Zhanmiao Yi^1*

1. Department of Pharmacy, Peking University Third Hospital, Beijing 100191, China,
2. Department of Pharmacy, Tsinghua University Yuquan Hospital, Beijing 100040, China,
3. Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China

Received:2016-12-27 Revised:2017-02-13 Online:2017-03-30 Published:2017-02-19
Contact: Tel.: +86-010-82265740, E-mail: yizhanmiao@163.com
Supported by:
The Medical Education Research Project from Society of Medical Education and Medical Education Committee of China Association of Higher Education (Grant No. 2016B-YX007).

摘要/Abstract

摘要：

本研究旨在系统评价联用细胞色素P(CYP)450酶抑制剂对伏立康唑安全性和药代动力学的影响。截至2016年1月26日, 计算机检索Cochrane图书馆、PubMed、Embase、CNKI、CBM、万方数据库和Clinicaltrials. gov, 收集有关联用 CYP450酶抑制剂对伏立康唑安全性与药代动力学参数影响的研究。两位作者独立检索文献, 提取数据并评价文献质量。用RevMan 5.3软件对符合纳入标准的研究进行Meta分析, 计算危险比(RRs)或均值差(MDs)及其95%置信区间。共纳入 12篇研究: 随机交叉研究3篇、单臂前后对照研究3篇、队列研究6篇。相比于伏立康唑单药组, 伏立康唑联用奥美拉唑组患者肝功能损害发生率明显升高(RR = 4.11, 95% CI 1.12–15.08, P = 0.03); 然而, 两药合用后神经毒性和视觉障碍的发生率并无统计学差异。此外, 泮托拉唑、雷贝拉唑、西咪替丁和口服避孕药可显著增加伏立康唑的血药峰浓度(Cmax)和药物-时间曲线下面积(AUC), 但是茚地那韦对伏立康唑的药动学无显著影响。艾司奥美拉唑、红霉素和阿奇霉素对伏立康唑的药动学参数影响结论不一致。除奥美拉唑外, 伏立康唑与CYP450酶抑制剂联用较为安全。尽管部分CYP450酶抑制剂会增加伏立康唑的Cmax和 AUC, 但未观察到临床意义。

关键词: 伏立康唑, 细胞色素P450酶抑制剂, 系统评价

Abstract:

Our objective was to systematically assess the effect of cytochrome P-450 (CYP450) inhibitors on pharmacokinetics and safety of voriconazole (VORI). Cochrane Library, PubMed, Embase, CNKI, CBM and WanFang databases and Clinicaltrials. gov were searched up to Jan. 26th 2016. Two reviewers independently identified studies, extracted data and assessed quality of studies. Meta-analysis was performed with RevMan 5.3, and risk ratios (RRs) and mean differences (MDs) with 95% confidence intervals (CIs) were calculated. A total of 12 studies were included: three crossover randomized controlled trials, three single-arm before-and-after studies and six cohort studies. Compared with non-combination group, the group of VORI plus omeprazole had a significantly higher occurrence of hepatic dysfunction (RR = 4.11, 95% CI 1.12–15.08, P = 0.03). However, neurologic dysfunction and visual disturbance were not significantly different. Pantoprazole, rabeprazole, cimetidine and contraceptive significantly increased the peak concentration (Cmax) and area under the curve (AUC) of VORI, while indinavir had no significant effect on pharmacokinetics of VORI. The effects of esomeprazole, erythromycin and azithromycin on pharmacokinetic parameters of VORI presented inconsistent results. Co-administration of VORI and CYP450 inhibitors was safe except for omeprazole. Although Cmax and AUC of VORI were increased while co-administered with a couple of CYP450 inhibitors, no significant effect on clinical outcomes was observed.

Key words: Voriconazole, Cytochrome P-450 inhibitors, Systematic review

中图分类号:

R969

Supporting:

杨会霞, 陈恳, 梁舒瑶, 翟所迪, 易湛苗. 合用CPY450酶抑制剂对伏立康唑安全性和药代动力学的影响的系统评价[J]. 中国药学(英文版), 2017, 26(3): 202-211.

Huixia Yang, Ken Chen, Shuyao Liang, Suodi Zhai, Zhanmiao Yi. Effect of cytochrome P-450 inhibitors on pharmacokinetics and safety of voriconazole[J]. Journal of Chinese Pharmaceutical Sciences, 2017, 26(3): 202-211.

参考文献

[1] Patterson, T.F.; Thompson, G.R.3rd; Denning, D.W.; Fishman, J.A.; Hadley, S.; Herbrecht, R.; Kontoyiannis, D.P.; Marr, K.A.; Morrison, V.A.; Nguyen, M.H.; Segal, B.H.; Steinbach, W.J.; Stevens, D.A.; Walsh, T.J.; Wingard, J.R.; Young, J.H.; Bennett, J.E. Clin. Infect. Dis. 2016, 63, e1-e60.

[2] Hamada, Y.; Tokimatsu, I.; Mikamo, H.; Kimura, M.; Seki, M.; Takakura, S.; Ohmagari, N.; Takahashi, Y.; Kasahara, K.; Matsumoto, K.; Okada, K.; Igarashi, M.; Kobayashi, M.; Mochizuki, T.; Nishi, Y.; Tanigawara, Y.; Kimura, T.; Takesue, Y. J. Infect. Chemother. 2013, 19, 381-392.

[3] Troke, P.F.; Hockey, H.P.; Hope, W.W. Antimicrob. Agents Chemother. 2011, 55, 4782-4788.

[4] Levin, M.D.; den Hollander J.G; van der Holt B; Rijnders, B.J.; van Vliet M; Sonneveld, P.; van Schaik R.H. J. Antimicrob. Chemother. 2007, 60, 1104-1107.

[5] Bruggemann, R.J.; Alffenaar, J.W.; Blijlevens, N.M.; Billaud, E.M.; Kosterink, J.G.; Verweij, P.E.; Burger, D.M. Clin. Infect. Dis. 2009, 48, 1441-1458.

[6] Hozo, S.P.; Djulbegovic, B.; Hozo, I. BMC Med. Res. Methodol. 2005, 5, 13.

[7] Racil, Z.; Winterova, J.; Kouba, M.; Zak, P.; Malaskova, L.; Buresova, L.; Toskova, M.; Lengerova, M.; Kocmanova, I.; Weinbergerova, B.; Timilsina, S.; Rolencova, M.; Cetkovsky, P.; Mayer, J. Mycoses. 2012, 55, 483-492.

[8] Wang, T.; Zhu, H.; Sun, J.; Cheng, X.; Xie, J.; Dong, H.; Chen, L.; Wang, X.; Xing, J.; Dong, Y. Int. J. Antimicrob. Agents. 2014, 44, 436-442.

[9] Wood, N.; Tan, K.; Purkins, L.; Layton, G.; Hamlin, J.; Kleinermans, D.; Nichols, D. Br. J. Clin. Pharmacol. 2003, 56, 56-61.

[10] Pascual, A.; Calandra, T.; Bolay, S.; Buclin, T.; Bille, J.; Marchetti, O. Clin. Infect. Dis. 2008, 46, 201-211.

[11] Cojutti, P.; Candoni, A.; Forghieri, F.; Isola, M.; Zannier, M.E.; Bigliardi, S.; Luppi, M.; Fanin, R.; Pea, F. Basic Clin. Pharmacol. Toxicol. 2016, 118, 474-479.

[12] Dolton, M.J.; Ray, J.E.; Chen, S.C.; Ng, K.; Pont, L.G.; McLachlan, A.J. Antimicrob. Agents Chemother. 2012, 56, 4793-4799.

[13] Mai, R.; Meng, D.; Xie, B.; Xia,o X.; Huang, S.; Cai, X.; Feng, F.; Li, Y.; Chen, W. International Medi. Health Guidance News. 2013, 19, 3687-3690.

[14] Purkins, L.; Wood, N.; Kleinermans, D.; Nichols, D. Br. J. Clin. Pharmacol. 2003, 56, 51-55.

[15] Purkins, L.; Wood, N.; Ghahramani, P.; Kleinermans, D.; Layton, G.; Nichols, D. Br. J. Clin. Pharmacol. 2003, 56, 30-36.

[16] Shi, H.Y.; Yan, J.; Zhu, W.H.; Yang, G.P.; Tan, Z.R.; Wu, W.H.; Zhou, G.; Chen, X.P.; Ouyang, D.S. Eur. J. Clin. Pharmacol. 2010, 66, 1131-1136.

[17] Andrews, E.; Damle, B.D.; Fang, A.; Foster, G.; Crownover, P.; LaBadie, R.; Glue, P. Br. J. Clin. Pharmacol. 2008, 65, 531-539.

[18] Purkins, L.; Wood, N.; Kleinermans, D.; Love, E.R. Br. J. Clin. Pharmacol. 2003, 56, 62-68.

[19] U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). U.S. Food & Drug Administration. 2012. This article can be found online at http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm292362.pdf

[20] Andersson, T.; Hassan-Alin, M.; Hasselgren, G.; Rohss, K.; Weidolf, L. Clin. Pharmacokinet. 2001, 40, 411-426.

[21] Shah, B.S.; Parmar, S.A.; Mahajan, S.; Mehta, A.A. Curr. Drug Metab. 2012, 13, 225-235.

[22] Chen, K.; Liu, W.; Wan, W.; Xiong, X.; Ke, X.; Zhai, S. Chin. J. Hosp. Pharm. 2016, 36, 871-872.

合用CPY450酶抑制剂对伏立康唑安全性和药代动力学的影响的系统评价

Effect of cytochrome P-450 inhibitors on pharmacokinetics and safety of voriconazole

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 10

编辑推荐

Metrics

本文评价

[1]	吴崇昊, 黄攀杰, 杨春琦, 高川, 曾鸣. 恶性胸膜间皮瘤免疫检查点抑制剂疗效及安全性meta分析[J]. 中国药学(英文版), 2023, 32(4): 291-301.
[2]	苏俐玫, 毛溪悦, 阳丽梅. 肺癌患者静脉血栓栓塞预防的疗效与安全性的meta分析[J]. 中国药学(英文版), 2023, 32(10): 852-860.
[3]	肖锐锐, 徐秀琴, 孙磊, 方晓磊, 肖鹏. 降心率药物伊伐布雷定安全性的系统评价[J]. 中国药学(英文版), 2017, 26(5): 379-389.
[4]	韩茹, 安雅晶, 赵荣生. α-酮酸对慢性肾脏病患者的附加作用: 一项随机对照试验的系统评价和meta分析[J]. 中国药学(英文版), 2017, 26(1): 63-75.
[5]	马卓, 崔向丽, 刘丽宏. 硫酸镁治疗成人哮喘急性发作的系统评价[J]. 中国药学(英文版), 2016, 25(8): 621-631.
[6]	董悦, 赵明, 胡欣. 替拉万星疗效及安全性的系统评价和Meta分析[J]. 中国药学(英文版), 2016, 25(3): 215-223.
[7]	刘园园, 梁舒瑶, 陈恳, 张帆, 刘芳. 伏立康唑对联合使用药物的药代动力学和安全性的影响: 系统评价[J]. 中国药学(英文版), 2016, 25(11): 785-798.
[8]	郭子寒, 焦园园, 易占苗, 李然, 张艳华. 癌症患者使用依维莫司会增加高血糖风险的系统评价[J]. 中国药学(英文版), 2015, 24(5): 326-335.
[9]	韩晟, 王宽, 濮润, 史录文^*. 软聚硅酮泡沫吸收敷料治疗压疮的药物经济学研究[J]. , 2013, 22(5): 456-460.
[10]	杨敏, 卢静, 蒋学华^*. 透明质酸治疗烧烫伤的系统评价[J]. , 2013, 22(3): 277-281.